References

Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease

10.1158/2159-8290.cd-21-0634 · 2021 · External reference

Commercial ctDNA assays for minimal residual disease detection of solid tumors

10.1007/s40291-021-00559-x · 2021 · External reference

Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: a systematic review and diagnostic accuracy meta-analysis

2026 · External reference

Clinical trial and real-world evidence of circulating tumor DNA monitoring to predict recurrence in patients with resected colorectal cancer

2024 · External reference

Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients

10.3389/fonc.2022.1069296 · 2022 · External reference

Real-world utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors

10.1200/oa-24-00084 · 2025 · External reference

Tumor-naive multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors

10.1177/17588359251393090 · 2025 · External reference

Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer

10.1002/1878-0261.13356 · 2023 · External reference

Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer

10.1038/s41523-025-00778-z · 2025 · External reference

Direct comparison of tumor-informed and tumor-naive circulating tumor DNA assays for recurrence detection in early-stage NSCLC

2026 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

The human genome browser at UCSC

10.1101/gr.229102 · 2002 · External reference

FATHMM-XF: accurate prediction of pathogenic point mutations via extended features

2018 · External reference

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

10.7554/elife.89083.3 · 2023 · External reference

A review on the impact of single-stranded library preparation on plasma cell-free diversity for cancer detection

10.3389/fonc.2024.1332004 · 2024 · External reference

Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

10.1038/s41587-021-00857-z · 2021 · External reference

GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients

10.1186/s12967-025-06993-3 · 2025 · External reference

Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer

10.1016/j.ccell.2023.08.010 · 2023 · External reference

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring

10.1038/s41591-020-0915-3 · 2020 · External reference

Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer

10.1158/1078-0432.ccr-19-3005 · 2020 · External reference

Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay

10.1158/1078-0432.ccr-24-1651 · 2024 · External reference

Abstract PS06-06: analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer

10.1158/1538-7445.sabcs23-ps06-06 · 2024 · External reference

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay

10.1016/j.esmoop.2025.104296 · 2025 · External reference

Cancer treatment monitoring using cell-free DNA fragmentomes

10.1038/s41467-024-53017-7 · 2024 · External reference

Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment

10.1038/s41591-024-03040-4 · 2024 · External reference

Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study

10.1002/1878-0261.13105 · 2022 · External reference

Prognostic value of postoperative circulating tumor DNA in patients with Early- and intermediate-stage hepatocellular carcinoma

2022 · External reference

Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma

10.1002/ctm2.793 · 2022 · External reference

Feasibility of personalized and tumor-informed circulating tumor DNA assay for early recurrence detection in patients with hepatocellular carcinoma

2025 · External reference

Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection

2023 · External reference